References
- Gaínza-Lein M, Sánchez Fernández I, Jackson M, et al. Association of time to treatment with short-term outcomes for pediatric patients with refractory convulsive status epilepticus. JAMA Neurol. 2018;75(4):410. doi: 10.1001/jamaneurol.2017.4382
- Gurcharran K, Grinspan ZM. The burden of pediatric status epilepticus: epidemiology, morbidity, mortality, and costs. Seizure. 2019;68:3–8. doi: 10.1016/j.seizure.2018.08.021
- McKenzie KC, Hahn CD, Friedman JN. Emergency management of the paediatric patient with convulsive status epilepticus. Paediatr Child Health. 2021 Jan 21;26(1):50–66. doi: 10.1093/pch/pxaa127
- Sathe AG, Underwood E, Coles LD, et al. Patterns of benzodiazepine underdosing in the established status epilepticus treatment trial. Epilepsia. 2021 Mar;62(3):795–806.
- Sánchez Fernández I, Abend NS, Agadi S, et al. Time from convulsive status epilepticus onset to anticonvulsant administration in children. Neurology. 2015 Jun 9;84(23):2304–11. doi: 10.1212/WNL.0000000000001673
- Fesler JR, Belcher AE, Moosa AN, et al. The efficacy and use of a pocket card algorithm in status epilepticus treatment. Neurol Clin Pract. 2021;11(5):406–412. doi: 10.1212/CPJ.0000000000000922
- Mctague A, Martland T, Appleton R. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev. 2018;2018(1). doi: 10.1002/14651858.CD001905.pub3
- Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American epilepsy society. Epilepsy Curr. 2016;16(1):48–61. doi: 10.5698/1535-7597-16.1.48
- Lawton B, Davis T, Goldstein H, et al. An update in the initial management of paediatric status epilepticus. Curr Opin Pediatr. 2018;30(3):359–363. doi: 10.1097/MOP.0000000000000616
- Vasquez A, Gaínza-Lein M, Sánchez Fernández I, et al. Hospital emergency treatment of convulsive status epilepticus: comparison of pathways from Ten pediatric research centers. Pediatr Neurol. 2018;86:33–41. doi: 10.1016/j.pediatrneurol.2018.06.004
- Hill CE, Parikh AO, Ellis C, et al. Timing is everything: where status epilepticus treatment fails. Ann Neurol. 2017;82(2):155–165. doi: 10.1002/ana.24986
- Chamberlain JM, Kapur J, Shinnar S, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020;395(10231):1217–1224. doi: 10.1016/S0140-6736(20)30611-5
- D’Onofrio G, Riva A, Amadori E, et al. Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care - an overview. Expert Opin Drug Metab Toxicol. 2022 Sep;18(9):575–585.
- Gospe SM Jr. Pyridoxine-Dependent Epilepsy – ALDH7A1. In: Adam M, Feldman J Mirzaa G, et al. Eds. GeneReviews® Internet. Seattle (WA): University of Washington, Seattle; 1993-2024 2001 Dec 7 [cited 2022 Sep 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1486/
- Wickstrom R, Taraschenko O, Dilena R, et al. International consensus recommendations for management of new onset refractory status epilepticus (NORSE) including febrile infection-related epilepsy syndrome (FIRES): summary and clinical tools. Epilepsia. 2022 Aug 11;63(11):2827–2839. doi: 10.1111/epi.17391
- Buratti S, Giacheri E, Palmieri A, et al. Ketamine as advanced second-line treatment in benzodiazepine-refractory convulsive status epilepticus in children. Epilepsia. 2023 Apr;64(4):797–810.
- Riva A, D’Onofrio G, Amadori E, et al. Current and promising therapeutic options for Dravet syndrome. Expert Opin Pharmacother. 2022 Oct;23(15):1727–1736.
- Haut SR, Nabbout R. Recognizing seizure clusters in the community: the path to uniformity and individualization in nomenclature and definition. Epilepsia. 2022 Sep;63(Suppl 1):S6–S13. doi: 10.1111/epi.17346